September 01, 2026 11:05 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
CJP calls off Sept 5 Delhi march after Supreme Court quashes FIRs against protesters | ‘Dismantle entire terror ecosystem’: Modi’s strong message at SCO Summit in Shehbaz’s presence | Modi’s big appeal after 7.8% GDP growth: ‘Don’t travel abroad, avoid destination weddings’ | Modi-Pezeshkian talks: Iran seeks India’s 'extensive contacts' to end West Asia war | Indus Waters Treaty row: India rejects Hague court order, says ‘no jurisdiction’ over its sovereign decisions | India beats the odds with 7.8% GDP growth; PM Modi has a message for critics | PM Modi meets Iranian President Masoud Pezeshkian during SCO summit in Kyrgyzstan | ‘Islam superior to all religions’: Karnataka minister’s remark sparks BJP-Congress war; resignation demand grows | PM Modi meets Iran's President Masoud Pezeshkian during SCO summit in Kyrgyzstan | VHP breaks silence on Durga Puja ‘guidelines’: No blanket non-veg ban, clarifies stand on theme pandals amid backlash
Stock Market
Representational Photo: ChatGPT

Bloodbath on Dalal Street! Sensex crashes over 700 points, Nifty down 200 points amid market panic

| @indiablooms | Jan 08, 2026, at 02:08 pm

Mumbai/IBNS: The Indian stock market witnessed a sharp sell-off on Thursday, with the BSE Sensex plummeting over 700 points and the NSE Nifty 50 sliding more than 200 points, media reports said.

The indices remained under pressure throughout the morning session, with Sensex touching an intraday low of 84,230.

Among the notable laggards in the Nifty 500 were Signature Global, Hindustan Zinc, National Aluminium, NMDC, Hindustan Copper, JSL and GMDC.

At around 1:30 pm, Punjab National Bank shares fell 2.13%, while Apex Frozen Foods plunged 7.56%, intensifying the market slide.

In the morning, shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.